Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients With Acute Intermittent Porphyria Who Have Completed a Previous Clinical Study With ALN-AS1

Next Previous
Trial Profile

A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients With Acute Intermittent Porphyria Who Have Completed a Previous Clinical Study With ALN-AS1

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Givosiran (Primary)
  • Indications Acute intermittent porphyria
  • Focus Adverse reactions
  • Sponsors Alnylam Pharmaceuticals

    • Most Recent Events

    • 24 Jun 2023 Final results assessing the safety and efficacy of up to48 months of givosiran treatment in patients with acute intermittent porphyria, presented at the European Association for the Study of the Liver Congress 2023.
    • 24 Jun 2023 Results assessing long-term treatment outcomes, qualitative interviews were conducted with study participants from Phase 1/2(NCT02949830) and Phase 3 (ENVISION; NCT03338816) studies, presented at the European Association for the Study of the Liver Congress 2023.
    • 09 Nov 2021 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top